Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Blood (2008) 112 (11): 92.

https://doi.org/10.1182/blood.V112.11.92.92

Published: 2008

Journal Articles

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Blood (2008) 112 (11): 1742.

https://doi.org/10.1182/blood.V112.11.1742.1742

Published: 2008

Journal Articles

Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma.

Iris Breitkreutz, MD, Marc S. Raab, MD, Sonia Vallet, MD, Teru Hideshima, MD, Noopur Raje, MD, Constantine Mitsiades, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 1184.

https://doi.org/10.1182/blood.V110.11.1184.1184

Published: 2007

Journal Articles

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Antonio Palumbo, MD, Alessandra Larocca, MD, Cecilia Rus, MD, Francesca Gay, MD, Davide Rossi, MD, Patrizia Pregno, MD, Patrizia Falco, MD, Ilaria Avonto, MD, Valeria Magarotto, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2007) 110 (11): 2715.

https://doi.org/10.1182/blood.V110.11.2715.2715

Published: 2007

Journal Articles

Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.

Cinara Echart, PhD, Barbara Graziadio, Cinzia Repice, Mario Boccadoro, MD, Antonio Palumbo, MD, Constantine Mitsiades, MD, Kenneth Anderson, MD, Paul Richardson, MD, Massimo Iacobelli, MD

Blood (2007) 110 (11): 2502.

https://doi.org/10.1182/blood.V110.11.2502.2502

Published: 2007

Journal Articles

Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors.

Cinara Echart, PhD, Maria Distaso, Laura Ferro, MD, Mario Boccadoro, MD, Antonio Palumbo, MD, Constantine Mitsiades, MD, Kenneth Anderson, MD, Paul Richardson, MD, Massimo Iacobelli, MD

Blood (2007) 110 (11): 2513.

https://doi.org/10.1182/blood.V110.11.2513.2513

Published: 2007

Journal Articles

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Blood (2007) 110 (11): 256.

https://doi.org/10.1182/blood.V110.11.256.256

Published: 2007

Journal Articles

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Teru Hideshima, MD, PhD, Noopur Raje, MD, Ruben Carrasco, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Tanyel Kiziltepe, PhD, Sonia Valet, MD, Samantha Pozzi, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 670.

https://doi.org/10.1182/blood.V110.11.670.670

Published: 2007

Journal Articles

Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma.

Simona Blotta, MD, Joeseph Negri, Purushothama Nanjappa, Anne-Sophie Moreau, MD, Rao Prabhala, PhD, Masood Shammas, PhD, Dheeraj Pelluru, PhD, Douglas McMillin, PhD, Yu-Tzu Tai, PhD, Pierfrancesco Tassone, MD, Kenneth C. Anderson, MD, Constantine Mitsiades, MD, PhD, Nikhil C. Munshi, MD

Blood (2007) 110 (11): 672.

https://doi.org/10.1182/blood.V110.11.672.672

Published: 2007

Journal Articles

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Antonio Palumbo, MD, Cecilia Rus, MD, Davide Rossi, MD, Patrizia Pregno, MD, Maria Teresa Ambrosini, MD, Ilaria Avonto, MD, Francesca Gay, MD, Federica Cavallo, MD, Massimo Iacobelli, MD, Gianluca Gaidano, MD, Constantine Mitsiades, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD, Mario Boccadoro, MD

Blood (2006) 108 (11): 3560.

https://doi.org/10.1182/blood.V108.11.3560.3560

Published: 2006

Journal Articles

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Hiroshi Yasui, MD, PhD, Laurence Catley, MD, Noopur Raje, MD, Dharminder Chauhan, PhD, Kenji Ishitsuka, MD, PhD, Klaus Podar, MD, PhD, Constantine Mitsiades, MD, PhD, Yu-Tzu Tai, PhD, Sonia Vallet, MD, Tanyel Kizitepe, PhD, Enrique Ocio, MD, PhD, Hiroshi Ikeda, MD, PhD, Yutaka Okawa, MD, PhD, Hiromasa Hideshima, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3410.

https://doi.org/10.1182/blood.V108.11.3410.3410

Published: 2006

Journal Articles

Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.

Noopur Raje, MD, Teru Hideshima, MD,PhD, Sonia Vallet, MD, Shweta Chhetri, Constantine Mitsiades, MD,PhD, Melissa Rooney, Hiroshi Yasui, Tanyel Kiziltepe, Klaus Podar, Yutaka Okawa, Hiroshi Ikeda, Dharminder Chauhan, Nikhil C. Munshi, Somesh Sharma, Himanshu Parikh, Bruce Chabner, Kenneth C. Anderson

Blood (2006) 108 (11): 3454.

https://doi.org/10.1182/blood.V108.11.3454.3454

Published: 2006

Journal Articles

Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, James E. Bradner, MD, Hiroshi Yasui, MD, PhD, Noopur Raje, MD, Dharminder Chauhan, PhD, Klaus Podar, MD, PhD, Yu-Tzu Tai, PhD, Constantine Mitsiades, MD, PhD, Paul G. Richardson, MD, Ralph Mazitschek, PhD, Stuart L. Schreiber, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 3426.

https://doi.org/10.1182/blood.V108.11.3426.3426

Published: 2006

Journal Articles

The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma.

Garrett O’Sullivan, Xavier Leleu, MD, Xiaoying Jia, Evdoxia Hatjiharisi, MD, Hai Ngo, Anne-Sophie Moreau, MD, Yu-Tsu Tai, PhD, Douglas McMillin, Constantine Mitsiades, MD, Noopur Raje, MD, Teru Hideshima, MD, Robert Schlossman, MD, Paul Richardson, MD, Nikhil Munshi, MD, Kenneth Anderson, MD, Irene Ghobrial, MD

Blood (2006) 108 (11): 3495.

https://doi.org/10.1182/blood.V108.11.3495.3495

Published: 2006

Journal Articles

Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage.

Siddhartha Mukherjee, MD, PhD, Noopur Raje, MD, Chirayu Patel, Sonia Vallet, MD, Joshua Aronson, Shweta Chhetri, Constantine Mitsiades, MD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD, David T. Scadden, MD

Blood (2006) 108 (11): 88.

https://doi.org/10.1182/blood.V108.11.88.88

Published: 2006

Journal Articles

The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.

Xiaoying Jia, Xavier Leleu, MD, Anne-Sophie Moreau, MD, Evdoxia Hatjiharisi, MD, Hai Ngo, Garrett O’Sullivan, Douglas McMillin, PhD, Steven Treon, MD, Constantine Mitsiades, MD, Teru Hideshima, MD, Michael Palladino, Kenneth Anderson, MD, Dharminder Chauhan, PhD, Irene Ghobrial, MD

Blood (2006) 108 (11): 4746.

https://doi.org/10.1182/blood.V108.11.4746.4746

Published: 2006

Journal Articles

Hsp90 Is Critical for the Regulation of Phenotype and Functionality of Human Dendritic Cells.

Jooeun Bae, PhD, Constantine Mitsiades, MD, Tai Yu-Tzu, PhD, Jeff Martinson, BS, Ramesh Babu Batchu, PhD, Robert Bertheau, BS, Cheng Li, PhD, Rao Prabhala, Shammas Masood, Teru Hideshima, Lawrence Catley, Kenneth Anderson, Nikhil Munshi

Blood (2005) 106 (11): 2401.

https://doi.org/10.1182/blood.V106.11.2401.2401

Published: 2005

Journal Articles

Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.

Teru Hideshima, MD, PhD, Laurence Catley, MD, Hiroshi Yasui, MD, PhD, Kenji Ishitsuka, MD, PhD, Noopur Raje, MD, Constantine Mitsiades, MD, PhD, Klaus Podar, MD, PhD, Nikhil C. Munshi, MD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 250.

https://doi.org/10.1182/blood.V106.11.250.250

Published: 2005

Journal Articles

Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial.

Paul G. Richardson, MD, Asher A. Chanan-Khan, MD, Melissa Alsina, MD, Deborah Doss, R.N., Beverly Landrigan, R.N., Dawn Kettner, N.P., Maher Albitar, MD, Constantine Mitsiades, MD, Gillian F. Cropp, MS, Robert G. Johnson, MD, Alison L. Hannah, MD, Kenneth C. Anderson, MD

Blood (2005) 106 (11): 361.

https://doi.org/10.1182/blood.V106.11.361.361

Published: 2005

Journal Articles

GRN163L, a Novel and Potent Telomerase Inhibitor, Inhibits Myeloma Cell Growth In Vitro and In Vivo .

Masood A. Shammas, PhD, Hemanta Koley, PhD, Pierfrancesco Tassone, MD, Paola Neri, MD, Alexei Protopopov, PhD, Sergei Gryaznov, PhD, Allison Chin, PhD, Robert C. Bertheau, Constantine Mitsiades, MD, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2005) 106 (11): 639.

https://doi.org/10.1182/blood.V106.11.639.639

Published: 2005

NARROW

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

Lenalidomide and Bortezomib: Targeting Osteoclastogenesis, Osteoclast Survival Factors, and Bone Remodeling Markers in Multiple Myeloma.

A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients.

Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide.

Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors.

Preclinical Validation of a Clinical Grade Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00 for the Treatment of Multiple Myeloma.

Delineation of Canonical and Non-Canonical NF-κB Pathways in Multiple Myeloma: Therapeutic Implications.

Hedgehog Pathway as a Potential Therapeutic Target in Multiple Myeloma.

A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients.

Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.

Targeting Cyclin D1 in the Treatment of Multiple Myeloma: Preclinical Validation of a Novel Specific Small Molecule Cyclin D1 Inhibitor, P276-00.

Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.

The Combination of the mTOR Inhibitor Rapamycin and Proteasome Inhibitor Bortezomib Is Synergistic In Vitro in Multiple Myeloma.

Bortezomib Induces Proliferation of Mesenchymal Progenitor Cells and Promotes Differentiation towards Osteoblastic Lineage.

The Proteasome Inhibitor NPI-0052 in Combination with Bortezomib Induces Antitumor Activity in Waldenstrom Macroglobulinemia.

Hsp90 Is Critical for the Regulation of Phenotype and Functionality of Human Dendritic Cells.

Perifosine, an Oral Bioactive Novel Alkyl-Phospholipid, Inhibits Akt and Induces In Vitro and In Vivo Cytotoxicity in Human Multiple Myeloma (MM) Cells.

Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial.

GRN163L, a Novel and Potent Telomerase Inhibitor, Inhibits Myeloma Cell Growth In Vitro and In Vivo .

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only